Press Releases

Company News
Summary ToggleAcura Pharmaceuticals Provides Development Update on Its LIMITX(TM) Abuse Deterrent Technology
Feb 01, 2016

Clinical Testing on LTX-04 to Commence in the First Quarter 2016

Read more

Summary ToggleAcura Pharmaceuticals Provides Development Update on Its LIMITX(TM) Abuse Deterrent Technology
Dec 17, 2015

Novel Oral Opioid Abuse Deterrent Technology

Read more

Summary ToggleAcura Pharmaceuticals Receives 2015 Frost & Sullivan North American Opioid Oral Abuse Deterrence Technology Innovation Award
Nov 10, 2015

Limitx(TM) Technology Recognized as Unique Among Existing Abuse Deterrent Technologies

Read more

Summary ToggleAcura Pharmaceuticals Announces Third Quarter 2015 Financial Results
Nov 04, 2015
PALATINE, IL -- (Marketwired) -- 11/04/15 -- Acura Pharmaceuticals, Inc. ( NASDAQ : ACUR) , a specialty pharmaceutical company developing products intended to address medication abuse and misuse, announced today financial results for the three and nine months ended September 30, 2015 .

Read more

Summary ToggleAcura Pharmaceuticals to Host Third Quarter 2015 Financial Results Conference Call on November 5, 2015
Oct 28, 2015
PALATINE, IL -- (Marketwired) -- 10/28/15 -- Acura Pharmaceuticals, Inc. ( NASDAQ : ACUR) , a specialty pharmaceutical company innovating abuse deterrent drugs , today announced that the Company plans to report financial results for third quarter 2015 following the close of financial markets on

Read more

Summary ToggleAcura Receives $2.5 Million Milestone Payment From Egalet Corporation
Oct 12, 2015

Associated With First Shipments of OXAYDO(TM)

Read more

Summary ToggleAcura Pharmaceuticals Meets NASDAQ's Continuing Listing Requirement
Sep 16, 2015
PALATINE, IL -- (Marketwired) -- 09/16/15 -- Acura Pharmaceuticals Inc. (NASDAQ: ACUR) (the "Company"), announced that on September 15, 2015 , the Company received a letter from the Listing Qualifications Staff (the "Staff") of The Nasdaq Stock Market confirming that for the last 10 consecutive

Read more

Summary ToggleEgalet Corporation Launches Acura Pharmaceuticals' OXAYDO(TM)
Sep 09, 2015

First and Only IR Oxycodone Designed to Discourage Abuse via Snorting

Read more

Summary ToggleAcura Pharmaceuticals Announces 1-for-5 Reverse Stock Split
Aug 24, 2015
PALATINE, IL -- (Marketwired) -- 08/24/15 -- Acura Pharmaceuticals Inc. (NASDAQ: ACUR) (the "Company"), announced today that it will effect a 1-for-5 reverse stock split of its common stock. At a special meeting of the Company's stockholders held earlier today, the stockholders approved an

Read more

Summary ToggleAcura Pharmaceuticals Announces Second Quarter 2015 Financial Results
Aug 03, 2015
PALATINE, IL -- (Marketwired) -- 08/03/15 -- Acura Pharmaceuticals, Inc. (NASDAQ: ACUR) , a specialty pharmaceutical company developing products intended to address medication abuse and misuse, announced today financial results for the three and six months ended June 30, 2015 .

Read more

Summary ToggleAcura Pharmaceuticals to Host Second Quarter 2015 Financial Results Conference Call on August 4, 2015
Jul 27, 2015
PALATINE, IL -- (Marketwired) -- 07/27/15 -- Acura Pharmaceuticals, Inc. (NASDAQ: ACUR) , a specialty pharmaceutical company innovating abuse deterrent drugs , today announced that the Company plans to report financial results for second quarter 2015 following the close of financial markets on

Read more

Summary ToggleAcura Pharmaceuticals to Raise Approximately $7.6 Million From Institutional Healthcare Investors
Jul 01, 2015
PALATINE, IL -- (Marketwired) -- 07/01/15 -- Acura Pharmaceuticals, Inc. (NASDAQ: ACUR) today announced it has entered into a Securities Purchase Agreement with certain institutional investors to sell 9,790,000 shares of common stock at a price of $0.78 per share, payable at closing.

Read more

Summary ToggleAcura Pharmaceuticals USPTO Issues Notice of Allowance for Novel Limitx(TM) Abuse Deterrent Technology
Jun 29, 2015

New Oral Opioid Abuse Technology

Read more

Summary ToggleAcura Pharmaceuticals Partners Its Methamphetamine Resistant Impede(R) Technology
Jun 16, 2015
PALATINE, IL -- ( Marketwired ) -- 06/16/15 -- Acura Pharmaceuticals, Inc. (NASDAQ: ACUR) today announced that Acura has entered into a License and Development Agreement with Bayer Healthcare LLC to provide an exclusive worldwide license to Acura's IMPEDE technology for use in an undisclosed

Read more

Summary ToggleAcura Pharmaceuticals Announces First Quarter 2015 Financial Results
May 04, 2015
PALATINE, IL -- ( Marketwired ) -- 05/04/15 -- Acura Pharmaceuticals, Inc. (NASDAQ: ACUR) , a specialty pharmaceutical company developing products intended to address medication abuse and misuse, announced today financial results for the first quarter ended March 31, 2015 .

Read more

Summary ToggleAcura Pharmaceuticals to Host First Quarter 2015 Financial Results Conference Call on May 5, 2015
Apr 21, 2015
PALATINE, IL -- ( Marketwired ) -- 04/21/15 -- Acura Pharmaceuticals, Inc. (NASDAQ: ACUR) , a specialty pharmaceutical company innovating abuse deterrent drugs ,  today announced that the Company plans to report financial results for first quarter 2015 following the close of financial markets on

Read more

Summary ToggleAcura Pharmaceuticals to Develop Abuse Deterrent Hydrocodone With Acetaminophen Tablets With Limitx(TM) Technology
Apr 09, 2015

Immediate-Release Tablets Intended to Address Excess Oral Consumption

Read more

Summary ToggleAcura Pharmaceuticals Reports Successful Topline Results From Nexafed(R) Extended-Release Clinical Study
Mar 23, 2015
PALATINE, IL -- ( Marketwired ) -- 03/23/15 -- Acura Pharmaceuticals, Inc. (NASDAQ: ACUR) , today announced preliminary topline results from a pilot clinical study which demonstrated bioequivalence of one formulation of NEXAFED (pseudoephedrine HCl) extended-release tablets to Sudafed® 12-Hour

Read more

Displaying 37 - 54 of 136 results